Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment
Environment International · 2024
DOI: 10.1016/j.envint.2023.108379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environment International, 2024. Verfasst von Cristiana Cannata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Science, Radboud Institute for Biological and Environmental Sciences (RIBES), Radboud University, Nijmegen, the Netherlan…. Hauptthemen laut MEDLINE: Environmental Monitoring, Water Pollutants, Chemical. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There are more than 3,500 active pharmaceutical ingredients (APIs) on the global market for human and veterinary use. Residues of these APIs eventually reach the aquatic environment. Although an environmental risk assessment (ERA) for marketing authorization applications of medicinal products is mandatory in the European Union since 2006, an ERA is lacking for most medicines approved prior to 2006 (legacy APIs). Since it is unfeasible to perform extensive ERA tests for all these legacy APIs, there is a need for prioritization of testing based on the limited data available. Prioritized APIs can then be further investigated to estimate their environmental risk in more detail. In this study, we prioritized more than 1,000 APIs used in Europe based on their predicted risk for aquatic freshwater ecosystems. We determined their risk by combining an exposure estimate (Measured or Predicted Environmental Concentration; MEC or PEC, respectively) with a Predicted No Effect Concentration (PNEC). We developed several procedures to combine the limited empirical data available with in silico data, resulting in multiple API rankings varying in data needs and level of conservativeness. In comparing empirical with in silico data, our analysis confirmed that the PEC estimated with the default parameters used by the European Medicines Agency often - but not always - represents a worst-case scenario. Comparing the ecotoxicological data for the three main taxonomic groups, we found that fish represents the most sensitive species group for most of the APIs in our list. We furthermore show that the use of in silico tools can result in a substantial underestimation of the ecotoxicity of APIs. After combining the different exposure and effect estimates into four risk rankings, the top-ranking APIs were further screened for availability of ecotoxicity data in data repositories. This ultimately resulted in the prioritization of 15 APIs for further ecotoxicological testing and/or exposure assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Environmental Science, Radboud Institute for Biological and Environmental Sciences (RIBES), Radboud University, Nijmegen, the Netherlands. Electronic address: cristiana.cannata@ru.nl.
- Department of Biological and Environmental Sciences, University of Gothenburg, Gothenburg, Sweden.
- Global Sustainability, AstraZeneca, Den Haag, the Netherlands.
- European Medicines Agency (EMA), Amsterdam, the Netherlands.
- Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
- Centre for Safety of Substances and Products (VSP), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Zitieren
APA
Cannata, C., Backhaus, T., Bramke, I., Caraman, M., Lombardo, A., Whomsley, R., Moermond, C. T. A., & Ragas, A. M. J. (2024). Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment. Environment International. https://doi.org/10.1016/j.envint.2023.108379
Vancouver
Cannata C, Backhaus T, Bramke I, Caraman M, Lombardo A, Whomsley R, et al. Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment. Environment International. 2024. doi:10.1016/j.envint.2023.108379
BibTeX
@article{Cannata2024,
author = {Cannata, Cristiana and Backhaus, Thomas and Bramke, Irene and Caraman, Maria and Lombardo, Anna and Whomsley, Rhys and Moermond, Caroline T A and Ragas, Ad M J},
title = {Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment},
journal = {Environment International},
year = {2024},
doi = {10.1016/j.envint.2023.108379}
}
EUVIMED